Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (US20170267694) Crystalline forms of an antiviral compound

Office : United States of America
Application Number: 15387318 Application Date: 21.12.2016
Publication Number: 20170267694 Publication Date: 21.09.2017
Grant Number: 09862728 Grant Date: 09.01.2018
Publication Kind : B2
IPC:
C07D 498/16
C07K 5/083
A61K 45/06
A61K 31/4985
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
12
in which the condensed system contains three hetero rings
16
Peri-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
5
Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof
04
containing only normal peptide links
08
Tripeptides
083
the side chain of the first amino acid being acyclic, e.g. Gly, Ala
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4985
Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Applicants: Gilead Sciences, Inc.
Inventors: Dustin Bringley
Johann Chan
Peter Fung
Katie Keaton
Olga Lapina
Henry Morrison
Dominika Pcion
Agents: Philip B. Polster
Priority Data:
Title: (EN) Crystalline forms of an antiviral compound
Abstract: front page image
(EN)

Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state:

embedded image
Also provided are processes of manufacture and methods of using the crystalline forms.